October 30, 2023
Allyx Therapeutics releases top-line Phase 1a data for ALX-001, demonstrating oral administration is safe and well-tolerated at all doses and achieves full brain receptor occupancy.
October 19, 2023
Allyx Therapeutics to Present Phase 1a Data for Lead Compound ALX-001 at the 16th Clinical Trials on Alzheimer’s Disease Meeting
Allyx Therapeutics aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases